Cystathionine γ-Lyase Identified as a Key Regulator of Memory and Learning
January 1, 2026
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
mosunetuzumab-axgb, Lunsumio
Synonyms :
mosunetuzumab
Class :
Anti-neoplastic, B-cell lymphoma inhibitors
Brand Name :
mosunetuzumab-axgb, Lunsumio
Synonyms :
mosunetuzumab
Class :
Anti-neoplastic, B-cell lymphoma inhibitors
Dosage Forms & Strengths
Injectable solution
1mg/ml
30mg/30ml
21-day cycle Day 1 Cycle 1: 1mg intravenous for 4 hours Day 8 Cycle 1: 2mg intravenous for 4 hours Day 1 Cycle 2: 60mg intravenous for 2 hours Day 15 Cycle 2: 60mg intravenous for 4 hours Cycle 3 and the following cycles Day 1: 30mg IV for 2 hours Restarting therapy 1mg administered last dose (Day 1 cycle 1) Week 1 and 2: Administer 2mg >2 week TO <6 weeks: administer 2 mg, then use 60 mg 2mg administered last dose (Day 8 cycle 1) Week 1 and 2: Administer 60mg >2 weeks: administer 1 mg, then use 2 mg >6 weeks: administer 1 mg and 2mg, then use 60 mg 60mg administered last dose (Day 15 cycle 1) Week 1 to <6 weeks: Administer 60mg >6 weeks: administer 1 mg and 2mg, then use 60 mg, followed by 30mg 60mg administered last dose (Day 1 cycle 2) Week 3 to <6 weeks: Administer 30mg >6 weeks: administer 1 mg and 2mg, then use 30 mg, followed by 30mg 30mg administered last dose (Cycle 3 and following cycles) Week 3 to <6 weeks: Administer 30mg >6 weeks: administer 1 mg on day 1 and 2mg on day 8, then use 30 mg on day 15, followed by 30mg on day 1 in the remaining cycles
Dosage Forms & Strengths
Safety and efficacy not established
Refer adult dosing
Frequency defined:
>10%
All grades
Decreased phosphate
Decreased WBC
Decreased platelets
Fatigue
Rash
Increased gamma-glutamyl transferase
Decreased potassium
Increased ALT
Musculoskeletal pain
Increased uric acid
Peripheral Neuropathy
Diarrhea
Dry skin
Chills
Arthralgia
Decreased lymphocyte count
Decreased hemoglobin
Decreased neutrophils
Increased glucose
Pyrexia
Cough
Pruritis
Edema
Upper respiratory tract infections
Grades 3 and 4
Decreased phosphate
Increased glucose
Decreased WBC
Decreased lymphocyte count
Increased glucose
Increased uric acid
Decreased hemoglobin
1-10%
All grades
Skin exfoliation
Urinary tract infections
Grades 3 and 4
Decreased platelets
Increased ALT
Rash
Pyrexia
Chills
Musculoskeletal pain
Abdominal pain
Increased GGT
Decreased potassium
Increased AST
Upper respiratory tract infections
Edema
Peripheral neuropathy
Dyspnea
Urinary tract infections
Pregnancy consideration: Insufficient data available
Lactation: Excretion of the drug in human breast milk is unknown
Pregnancy category:
Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.
Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.
Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.
Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.
Category N: There is no data available for the drug under this category
Patient information leaflet
Generic Name: mosunetuzumab
Pronounced: (moe sun” e tooz’ ue mab)
Why do we use mosunetuzumab?
It is used to treat relapsed follicular lymphoma
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
